Table 1.
Baseline characteristics of included studies.
| Author | Study Design | PTC and HT Diagnosis | Grouping | N Patients | Age (Years) | Female (%) | BRAF (+) N (%) |
|---|---|---|---|---|---|---|---|
| Kim et al., 2009, South Korea | R | PTC: Histopathology HT: Histopathology |
PTC | 64 | 44.1 ± 13.4 | 84.4 | 61 (95.31) |
| PTC-HT | 37 | 49.4 ± 12.7 | 97.3 | 27 (72.97) | |||
| Marotta et al., 2013, Italy | P | PTC: Histopathology HT: Histopathology |
PTC | 92 | 56.1 | 71.7 | 72 (78.26) |
| PTC-HT | 54 | 50.2 | 92.6 | 44 (81.48) | |||
| Kim et al., 2016, South Korea | R | PTC: Histopathology HT: Histopathology |
PTC | 2326 | 47.6 ± 11.9 | 72.5 | 2015 (86.63) |
| PTC-HT | 1006 | 46 ± 11.4 | 90.7 | 774 (76.94) | |||
| Zeng et al., 2016, China | R | PTC: Histopathology HT: Histopathology |
PTC | 397 | 45.5 ± 11.8 | 72.8 | 325 (81.86) |
| PTC-HT | 222 | 45.9 ± 12.1 | 87.8 | 140 (63.06) | |||
| Kim et al., 2018, South Korea | R | PTC: NR HT: Histopathology |
PTC | 124 | 50.06 ± 11.51 | 86.3 | 102 (82.26) |
| PTC-HT | 48 | 46.44 ± 10.62 | 93.8 | 28 (58.33) | |||
| Ozdamar et al., 2020, Turkey | P | PTC: Cytopathology HT: Histopathology |
PTC | 19 | 45.68 ± 14.3 | 84.2 | 6 (31.58) |
| PTC-HT | 18 | 47.94 ± 14.84 | 100 | 5 (27.78) | |||
| Kim et al., 2005, South Korea | R | PTC: Histopathology HT: Histopathology |
PTC | 51 | NR | NR | 46 (90.20) |
| PTC-HT | 28 | NR | NR | 18 (64.29) | |||
| Kim et al., 2016a, South Korea | P | PTC: NR HT: Histopathology |
PTC | 1576 | 47.2 ± 12.0 | 81.8 | 1223 (77.60) |
| PTC-HT | 204 | 44.8 ± 11.9 | 97 | 122 (59.80) | |||
| Issa et al., 2022, Switzerland | R | PTC: NR HT: Sonography and Serology |
PTC | 106 | NR | 75.3 | 52 (49.06) |
| PTC-HT | 23 | NR | 85.2 | 9 (39.13) |
R, retrospective; P, prospective; PTC, Papillary thyroid carcinoma; HT, Hashimoto thyroiditis; NR, not reported.